Carlo Rizzuto is a Venture Partner with Versant Ventures and focuses on biotech investing and company building. He also serves as CEO of Highline Therapeutics, Versant’s New York City-based incubator.

Carlo joined Versant from Novartis Pharmaceuticals where he led global product development teams in the advancement of innovative pipeline products. He previously held the position of Associate Principal with McKinsey & Company advising U.S. and European clients in the pharmaceutical, payor, and provider sectors. Prior to joining McKinsey, Carlo helped found engeneOS, a Boston-based biotech startup.

Carlo received a PhD in Virology from Harvard University and a BA in Biology from the University of Virginia.

Page 1 of 1